Evidence map›Paper›PMID 39445075›Full record

ArticleFrontiers in neuroscience2024

SHARD: an improved method for staining and visualizing multiplex immunofluorescence in optically cleared postmortem human brain tissue.

Grace A Rosen, Daniel Kirsch, Raymond Nicks, Hunter Kelley, Rebecca Mathias, Kerry A Cormier, Caroline A Kubilus, Bryan Dec, Thor D Stein, Victor E Alvarez and 3 more

Abstract read
In one paragraph

Article in Frontiers in neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Grace A RosenVA Boston Healthcare System, US Department of Veterans Affairs, Boston, MA, United States.
Daniel KirschDepartment of Pathology and Laboratory Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, United States.
Raymond NicksBoston University Alzheimer's Disease Research Center and Boston University CTE Center, Boston, MA, United States.
Hunter KelleyVA Boston Healthcare System, US Department of Veterans Affairs, Boston, MA, United States.
Rebecca MathiasVA Boston Healthcare System, US Department of Veterans Affairs, Boston, MA, United States.
Kerry A CormierVA Boston Healthcare System, US Department of Veterans Affairs, Boston, MA, United States.
Caroline A KubilusDepartment of Neurology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, United States.
Bryan DecBoston University Alzheimer's Disease Research Center and Boston University CTE Center, Boston, MA, United States.
Thor D SteinVA Boston Healthcare System, US Department of Veterans Affairs, Boston, MA, United States.
Victor E AlvarezVA Boston Healthcare System, US Department of Veterans Affairs, Boston, MA, United States.
Michael L AloscoDepartment of Neurology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, United States.
Ann C McKeeVA Boston Healthcare System, US Department of Veterans Affairs, Boston, MA, United States.
Bertrand R HuberVA Boston Healthcare System, US Department of Veterans Affairs, Boston, MA, United States.

Funding

RL5: Research Education CoreP30AG072978 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Lindsay A. Farrer · 2021 to 2026
$25.6M
Traumatic Brain Injury and Repetitive Head Impacts: Contributions to AD/ADRD and CTE Neuropathology and Resulting Clinical SyndromesU54NS115266 · NINDS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI STEIN, THOR · 2019 to 2023
$10.3M
Clinical Features and Neuropathological Basis of Sleep Wake Behavior in Alzheimer's and PSPR01AG060477 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Lea Tenenholz Grinberg, Thomas C Neylan · 2019 to 2026
$8.2M
Late Pathologies of Exposure to Repetitive Head Impacts from Contact Sports: White Matter and Vascular Contributions to Cognitive Impairment, Dementia, and Neuropsychiatric SymptomsRF1NS122854 · NINDS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ALOSCO, MICHAEL, MCKEE, ANN C. · 2021 to 2021
$2.3M
Investigating Fear System Myelination in PTSD Using In Vivo and Post Mortem DataR01MH132617 · NIMH · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI HUBER, BERTRAND R, NEYLAN, THOMAS C · 2023 to 2025
$2.1M
Late Pathologies of Exposure to Repetitive Head Impacts from Contact Sports: White Matter and Vascular Contributions to Cognitive Impairment, Dementia, and Neuropsychiatric SymptomsR01NS122854 · NINDS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ALOSCO, MICHAEL, MCKEE, ANN C. · 2024 to 2025
$1.6M
Tau Pathology in Motor Regions and Parkinsonism in Chronic Traumatic Encephalopathy: A Comparison to Progressive Supranuclear Palsy and Corticobasal DegenerationF31NS127449 · NINDS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI KIRSCH, DANIEL A · 2022 to 2025
$193k
BLRD VA I01 BX005933NIA NIH HHS P30 AG072978NIA NIH HHS R01 AG060477NIMH NIH HHS R01 MH132617NINDS NIH HHS F31 NS127449NINDS NIH HHS RF1 NS122854NINDS NIH HHS U54 NS115266
6 · The paper itself

Abstract

Postmortem human brain tissue is a critical resource for studying neurodegenerative disease, providing critical insights into cellular morphology, pathology, and network connectivity. To improve standard microscopy and enable high-resolution, three-dimensional (3D) images of tissues at the subcellular level, tissue-clearing methods have been developed. These 3D images allow for the analysis of large regions of interest and can be used to study structural and spatial changes that occur during neurodegeneration. Additionally, 3D imaging facilitates the visualization of whole-cell morphology, especially in cells with long processes that would otherwise be truncated in single-plane images. Human brain tissue is especially challenging for tissue clearing due to the abundance of lipids in myelin and the need for optimal fixation and low postmortem intervals. Formaldehyde-based fixatives, commonly used in preserving tissue, hinder antibody binding by crosslinking important antibody epitopes, and fluorescent microscopy requires the incorporation of fluorescent labels through passive diffusion or electrophoresis. Recent studies have focused on optimally fixed human brain tissue with short postmortem intervals, limiting the general applicability of these methods. To address these challenges, we developed SHARD (SHIELD, antigen retrieval, and delipidation), a simple and widely applicable method for clearing and labeling human brain tissue, which can be applied to long-term banked human brain tissue preserved in formaldehyde. SHARD is a novel addition to the SHIELD tissue clarification method, combining antigen retrieval, tissue clearing, and staining of 200-μm sections from long-term banked human brain tissue. The SHARD method is effective for postmortem intervals (PMIs) ranging from 10 to 72 h in multiple neurodegenerative diseases and control samples. In this study, we demonstrate that the SHARD method significantly enhances the immunostaining of glial fibrillary acidic protein (GFAP), an astrocytic cytoskeletal marker. Overall, the combination of antigen retrieval and tissue delipidation holds great potential for achieving detailed 3D immunostaining in long-term formaldehyde-fixed postmortem human brain tissue, opening new avenues for research and discovery.

Indexed as

3D confocal imaging3D confocal laser scanning microscopyantigen retrievalhuman brain bankingimmunofluorescenceoptical clearingvolumetric imaging

Identifiers

PMID39445075
PMCPMC11496292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.